Semaglutide Side Effects: Safety Signals and Warnings
Semaglutide safety concerns are compound-specific. The main listed side effects are Nausea (most common, usually transient), Vomiting, and Diarrhea. The main warning signals are Boxed warning: thyroid C-cell tumors in rodents, Contraindicated with personal/family history of medullary thyroid carcinoma, and Risk of pancreatitis.
Direct Answer
Semaglutide remains the most broadly validated single-receptor GLP-1 medicine. Tirzepatide produces greater average weight loss in direct comparison, while semaglutide has mature cardiovascular outcomes evidence plus approved oral, kidney, and MASH uses across its product family.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Evidence context
- Evidence-backed obesity, type 2 diabetes, cardiovascular, kidney, and MASH indications
Reported Side Effects
- Nausea (most common, usually transient)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Injection site reactions
Warnings
- Boxed warning: thyroid C-cell tumors in rodents
- Contraindicated with personal/family history of medullary thyroid carcinoma
- Risk of pancreatitis
- May worsen diabetic retinopathy
- Not for use with insulin or other GLP-1 agonists
- Gallbladder events reported
Known or Plausible Interactions
- Insulin (increased hypoglycemia risk)
- Sulfonylureas (increased hypoglycemia risk)
- Oral medications (delayed absorption due to slowed gastric emptying)
- Warfarin (monitor INR closely)
Regulatory Context
FDA-approved products include Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management and cardiovascular risk reduction in qualifying patients. FDA approved a 25 mg oral Wegovy tablet in December 2025 and a 7.2 mg weekly Wegovy injection for adults with obesity in March 2026. Wegovy also has accelerated approval for adults with noncirrhotic MASH and moderate-to-advanced fibrosis; continued approval may depend on confirmatory benefit.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Weight Loss (Level A), Blood Sugar Control (Level A), Cardiovascular Protection (Level A), and MASH (Level A) |
| Primary citation count | 6 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Semaglutide?
Semaglutide safety concerns are compound-specific. The main listed side effects are Nausea (most common, usually transient), Vomiting, and Diarrhea. The main warning signals are Boxed warning: thyroid C-cell tumors in rodents, Contraindicated with personal/family history of medullary thyroid carcinoma, and Risk of pancreatitis.
What is the evidence level for Semaglutide?
Semaglutide is rated Level A. Its current research status is FDA Approved.
What is Semaglutide best known for?
Evidence-backed obesity, type 2 diabetes, cardiovascular, kidney, and MASH indications.
Where can I read the full Semaglutide evidence review?
The full evidence review is available at https://examinepeptides.com/library/semaglutide.
Related Guides
How to Cite This Page
ExaminePeptides. "Semaglutide Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/semaglutide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.